Published in Dig Dis Sci on October 06, 2010
Clostridium difficile infection: new insights into management. Mayo Clin Proc (2012) 1.23
Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol (2016) 1.13
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe (2015) 1.00
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun (2014) 0.94
A case of toxic megacolon caused by clostridium difficile infection and treated with fecal microbiota transplantation. Gut Liver (2015) 0.91
Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc (2012) 0.86
Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol (2016) 0.86
Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr (2013) 0.85
WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg (2015) 0.85
An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol (2016) 0.80
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79
Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist (2013) 0.79
Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. Am J Gastroenterol (2016) 0.78
Hematologic diseases: high risk of Clostridium difficile associated diarrhea. World J Gastroenterol (2014) 0.77
Intravenous immunoglobulin in treatment of Clostridium difficile colitis. BMJ Case Rep (2012) 0.77
Management of Clostridium difficile Infection. Gastroenterol Hepatol (N Y) (2016) 0.75
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther (2016) 0.75
Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration. Clin Exp Immunol (2017) 0.75
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection. Clin Vaccine Immunol (2016) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ (2004) 9.93
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis (2006) 7.64
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg (2002) 4.91
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis (2005) 4.42
Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis (2004) 3.42
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis (2005) 2.68
Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis (2008) 2.61
Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis (1990) 2.17
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis (1983) 2.03
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr (1991) 1.97
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology (1979) 1.80
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol (2007) 1.70
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Severe Clostridium difficile colitis. Dis Colon Rectum (1995) 1.59
Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill (2007) 1.55
Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum (2006) 1.49
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother (2004) 1.33
Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis (1992) 1.32
Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology (1992) 1.32
Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med (2010) 1.19
Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol (2004) 1.19
Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection (1985) 1.18
Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control (2007) 1.13
Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis (1993) 1.11
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol (2004) 1.06
Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother (2007) 1.06
Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun (1995) 1.05
Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg (1995) 1.04
Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis (1994) 0.96
Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol (2004) 0.95
Cytotoxin and enterotoxin production by Clostridium difficile. Microbiologica (1984) 0.94
Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods (1983) 0.92
Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun (1989) 0.91
Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis (1995) 0.90
Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett (2005) 0.87
Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut (2002) 0.81
Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing (2005) 0.81
Successful treatment of Clostridium difficile colitis with intravenous immunoglobulin. J Gastrointestin Liver Dis (2008) 0.77
Refractory Clostridium difficile-associated diarrhea. MedGenMed (2007) 0.75
MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology (2008) 3.29
Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis (2010) 1.89
Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2010) 1.38
The Role of MicroRNA in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2010) 1.22
The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One (2011) 1.20
MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.19
Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer (2011) 1.03
NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells. Inflamm Bowel Dis (2014) 0.98
Multiphasic analysis of the temporal development of the distal gut microbiota in patients following ileal pouch anal anastomosis. Microbiome (2013) 0.96
IL-23 receptor regulation by Let-7f in human CD4+ memory T cells. J Immunol (2011) 0.96
Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells. Inflamm Bowel Dis (2010) 0.87
Novel players in inflammatory bowel disease pathogenesis. Curr Gastroenterol Rep (2012) 0.87
Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm Bowel Dis (2011) 0.85
miR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells. Inflamm Bowel Dis (2013) 0.84
Translational repression of SLC26A3 by miR-494 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2013) 0.79
Ulcerative Colitis-Associated Long Noncoding RNA, BC012900, Regulates Intestinal Epithelial Cell Apoptosis. Inflamm Bowel Dis (2016) 0.76
Corrigendum: TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Sci Rep (2016) 0.76
Divergent influence of microRNA-21 deletion on murine colitis phenotypes. Inflamm Bowel Dis (2014) 0.75